The Six Food Elimination in Postprandial Distress Syndrome
NCT ID: NCT05651386
Last Updated: 2024-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
15 participants
INTERVENTIONAL
2020-02-19
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Symptoms will be monitored with a daily diary (LPDS diary) and food intake will be evaluated during 2 weeks.
If there is an improvement of symptoms during the diet, a reintroduction period will start. This period will last 6 weeks. Every 2 weeks, two food groups will be reintroduced. When there is a clear worsening in symptoms, a new endoscopy with biopsies will be performed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Confocal Laser Endomicroscopy Based Diet in Functional Dyspepsia
NCT05666154
Functional Dyspepsia: Validation of a Questionnaire for Symptom Assessment in FD PDS Subgroup
NCT04647955
Effect of Secretin in Functional Dyspepsia and Healthy Subjects
NCT03617861
Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia
NCT05718960
Influence of Bile Acids on Bacterial Uptake in Functional Dyspepsia
NCT03296267
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study design includes 8 weeks of a strict 6 food elimination diet, followed by an 8 week reintroduction phase in patients with symptom improvement. The duration of 8 weeks is based on the effect of the 6 FED in eosinophilic esophagitis.
Each subject will undergo a screening before the start of the diet. During the screening visit, all study procedures will be explained, the informed consent form will be signed by the participant, and the inclusion and exclusion criteria will be checked by revising the participant's medical history and by using screening GI symptom questionnaires (Rome IV questionnaire).
The screening visit will include a physical examination, medical history and a blood sample for IgE testing to exclude typical food allergies.
When eligibility is confirmed during the screening visit, a fourteen-day period starts. In this period, the LPDS diary (Leuven Postprandial distress syndrome) and food diary will be filled out on a daily basis to assess symptoms at baseline. The food diary will be available via an application for mobile phones or online use. The Comprehensive Nutrition Assessment Questionnaire will be filled in to analyse baseline food intake.
At visit 1, following tests will be conducted in a 2-day period (outpatient clinic):
* A gastroduodenoscopy with biopsies, optionally/preferably under sedation.
* A gastric barostat study.
* A gastric emptying breath test. If desired, the gastric emptying test can be performed at home and sent or taken to the clinic.
* Questionnaires (as specified in chapter 10.3.) After these tests, the 6 food elimination diet (6FED) will be explained by a trained dietician.
The diet will be followed during 8 weeks under supervision of this dietician with experience in eosinophilic esophagitis.
During the 6FED the compliance of patients will be evaluated by the use of diet diaries from week 6 to 8. Symptoms will be evaluated throughout the 8-week dietary restriction period using the daily LPDS diary. Patients will report daily food intake via an application for mobile phone or online use during two weeks of the diet period.
A telephone call will be scheduled after two and six weeks, to assess compliance.
After 8 weeks of six food elimination diet, a new gastroduodenoscopy with biopsies will be performed, as well as a new gastric barostat and gastric emptying breath test, as described at visit 1.
At visit 2, patients with a symptom improvement, defined as an average LPDS with 0.5 point or more compared to baseline will be sent for a consultation with our dietician for the explanation of reintroduction of nuts and fish.
This will be done in a non-blinded way.
During the reintroduction period, patients will visit the hospital every 2 weeks for visit 3, 4 and 5. First, fish and nuts will be reintroduced, than eggs and soy and lastly gluten and milk. Patients with symptom worsening, defined as an average LPDS with 0.5 point or more compared to the end of the 6FED diet period, will be invited to undergo a with gastroscopy with biopsies and a new blood sample for PBMCs.
During the entire study, patients will fill in the daily diary (LPDS).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Six food elimination diet
The six food elimination diet will be performed in all subjects.
Diet
No blinded, no controlled intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diet
No blinded, no controlled intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Witnessed written informed consent prior to any study procedures
* Patients aged between 18 and 70 years inclusive
* Male or female patients
* Women of child-bearing potential agree to apply a highly effective method of birth control during the entire duration of the trial. Women of non-childbearing potential may be included if surgically sterile or postmenopausal with at least 2 year without spontaneous menses.
* Subject is capable to understand the study and the questionnaires, and to comply with the study requirements.
Exclusion Criteria
* Organic gastro-intestinal disease
* Major psychiatric disorder
* Patients with eosinophilic esophagitis
* Presence of diabetes mellitus
* Presence of coeliac disease, lupus, scleroderma and other systemic auto-immune disease.
* Active H. Pylori infection or \< 6 months after eradication
* Predominant irritable bowel syndrome (IBS)
* Predominant gastro-oesophageal reflux disease (GERD)
* Atopic constitution or food allergy
* Ongoing diet which interferes with the 6 food elimination diet.
* Drugs altering gastric emptying or anti-inflammatory drugs
* Females who are pregnant or lactating
* Patients not capable to understand or be compliant with the study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jan Tack, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
KU Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KU Leuven
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
s63494
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.